1781-83-5Relevant articles and documents
Sands,Botteron
, p. 2690 (1963)
Palladium catalyzed synthesis of some novel (Spirocycloalkenyl) trimethylsilylacetylenes
Venkatesha, Manjunatha Achanna,Suresh, HariPrasad
, p. 457 - 461 (2013/08/23)
The synthesis of some novel (spirocycloalkenyl)trimethylsilylacetylenes employing the Sonogashira coupling reaction of the corresponding novel spirocycloalkenyliodides with trimethylsilylacetylene and Pd(PPh3)2Cl2/CuI catalyst in yields ranging 79-84% is reported. The compounds would serve as novel (spirocycloalkenyl)acetylenic anionic synthons.
Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: Effects of substitution about the rigidifying ring
Koenig, John R.,Liu, Huaqing,Drizin, Irene,Witte, David G.,Carr, Tracy L.,Manelli, Arlene M.,Milicic, Ivan,Strakhova, Marina I.,Miller, Thomas R.,Esbenshade, Timothy A.,Brioni, Jorge D.,Cowart, Marlon
scheme or table, p. 1900 - 1904 (2010/07/08)
Three novel series of histamine H4 receptor (H4R) antagonists containing the 2-aminopyrimidine motif are reported. The best of these compounds display good in vitro potency in both functional and binding assays. In addition, representative compounds are able to completely block itch responses when dosed ip in a mouse model of H4-agonist induced scratching, thus demonstrating their activities as H4R antagonists.
GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS
-
Page 48, (2010/02/08)
The invention relates to guanidine derivatives of formula (I) where: A = a chain of 3-c6 carbon atoms, one of which can be replaced by -N(R')- or -O- and R' = H or a substituent, where the ring skeleton only contains both double bonds of the thiazole component, the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I),, comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which are partly known and partly novel and exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence. The above can be produced using generally used methods and processed to give medicaments.
